784156-32-7

Basic information

• Product Name: 1-Benzyl 5-Methyl N,N-bis(tert-butoxycarbonyl)-D-glutaMate
• Synonyms: 1-Benzyl 5-Methyl N,N-bis(tert-butoxycarbonyl)-D-glutaMate;RQXXACXWPFWUMW-QGZVFWFLSA-N
• CAS NO: 784156-32-7
• Molecular Formula: C₂₃H₃₃NO₈
• Molecular Weight: 451.51002
• Mol File: 784156-32-7.mol

Chemical Properties

• Boiling Point: 514°C at 760 mmHg
• Flash Point: 264.7°C
• Appearance: /
• Density: 1.153g/cm³
• Vapor Pressure: 1.12E-10mmHg at 25°C
• Refractive Index: 1.504
• CAS DataBase Reference: 1-Benzyl 5-Methyl N,N-bis(tert-butoxycarbonyl)-D-glutaMate(CAS DataBase Reference)
• NIST Chemistry Reference: 1-Benzyl 5-Methyl N,N-bis(tert-butoxycarbonyl)-D-glutaMate(784156-32-7)
• EPA Substance Registry System: 1-Benzyl 5-Methyl N,N-bis(tert-butoxycarbonyl)-D-glutaMate(784156-32-7)

Safety Data

• Hazardous Substances Data: 784156-32-7(Hazardous Substances Data)

Usage

InChI:InChI=1/C23H33NO8/c1-22(2,3)31-20(27)24(21(28)32-23(4,5)6)17(13-14-18(25)29-7)19(26)30-15-16-11-9-8-10-12-16/h8-12,17H,13-15H2,1-7H3/t17-/m1/s1

Upstream product

• 883985-06-6 C₁₈H₂₅NO₆ 
• 24424-99-5 di-tert-butyl dicarbonate 
• 34404-30-3 N-(tert-butoxycarbonyl)-D-glutamic acid 1-benzyl ester 
• 18107-18-1 diazomethyl-trimethyl-silane 

Downstream Products

• 784156-34-9 (R)-benzyl 2-[bis(tert-butoxycarbonyl)amino]-5-oxopentanoate 
• 784156-33-8 benzyl (2R,5E)-2-[bis(tert-butoxycarbonyl)amino]-6-nitrohex-5-enoate 
• 784156-96-3 (5S)-N₂,N₂-bis(tert-butoxycarbonyl)-5-(2,3-difluorophenyl)-D-lysine 
• 781650-32-6 tert-butyl [(3R,6S)-6-(2,3-difluorophenyl)-2-oxoazepan-3-yl]carbamate 
• 880144-45-6 benzyl (5S)-N,N-bis(tert-butoxycarbonyl)-5-(2,3-difluorophenyl)-6-nitro-D-norleucinate 
• 781650-41-7 (3R,6S)-3-amino-6-(2,3-difluorophenyl)-1-(2,2,2-trifluoroethyl)azepan-2-one 
• 784156-57-6 di-tert-butyl [(3R,6S)-6-(2,3-difluorophenyl)-1-(2-hydroxy-2-methylpropyl)-2-oxoazepan-3-yl]imidodicarbonate 
• 880144-46-7 tert-butyl (3R,6S)-6-(2,3-difluorophenyl)-2-thioxoazepan-3-ylcarbamate 
• 880144-47-8 tert-butyl {(6S,9R)-6-(2,3-difluorophenyl)-3-[1-(trifluoromethyl)cyclopropyl]-6,7,8,9-tetrahydro-5H-imidazo[1,2-a]azepin-9-yl}carbamate 
• 880144-52-5 tert-butyl [(6S,9R)-6-(2,3-difluorophenyl)-3-(2,2,2-trifluoroethyl)-6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepin-9-yl]carbamate 
• 880144-53-6 tert-butyl (3R,6S)-6-(2,3-difluorophenyl)-2-hydrazonoazepan-3-ylcarbamate 
• 784156-56-5 (3R,6S)-3-amino-6-(2,3-difluorophenyl)-1-(2-hydroxy-2-methylpropyl)azepan-2-one trifluoroacetic acid salt 
• 1092935-86-8 tert-butyl [(2Z,3R,6S)-6-(2,3-difluorophenyl)-2-({2-hydroxy-2-[1-(trifluoromethyl)cyclopropyl]ethyl}imino)azepan-3-yl]carbamate 

Relevant articles and documents

CARBOXAMIDE HETEROCYCLIC CGRP RECEPTOR ANTAGONISTS

Compounds of formula I: I wherein variables A1, A2, B, m, n, J, R4, G1, G2, G3 and Y are as described herein, which are antagonists of CGRP receptors and which are useful in the treatment or prevention of diseases in which the CGRP is involved, such as mi

Synthesis of the (3R,6S)-3-amino-6-(2,3-difluorophenyl)azepan-2-one of telcagepant (MK-0974), a calcitonin gene-related peptide receptor antagonist for the treatment of migraine headache

(Chemical Equation Presented) Two novel routes have been developed to the (3R,6S)-3-amino-6-(2,3-difluorophenyl)-1-(2,2,2-trifluoroethyl)azepan-2-one 2 of the CGRP receptor antagonist clinical candidate telcagepant (MK-0974, 1). The first employs a ring-closing metathesis of the styrene 7 as the key reaction, while the second makes use of a highly diastereoselective Hayashi-Miyaura Rh-catalyzed arylboronic acid addition to nitroalkene 16. The latter route has been implemented to produce multigram quantities of telcagepant for extensive preclinical evaluation.

CGRP RECEPTOR ANTAGONISTS

Compounds of Formula I and formula II (where variables D, R2, R4, A, B, W, X, Y and Z are as defined herein) useful as antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which the CGRP is involved,

CGRP RECEPTOR ANTAGONISTS

The present invention is directed to compounds of Formula I: Formula I: I and Formula II: (where variables R1, R2, R3, R4, A, B, J, Q, T, V, W, X and Y are as defined herein) useful as antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which the CGRP is involved, such as headache, migraine and cluster headache. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.

CGRP RECEPTOR ANTAGONISTS

Compounds of Formula (I) and Formula (II) (where variables R1, R2, R4, A, B, W, X, Y and Z are as defined herein) useful as antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which the CGRP is involved, such as headache

CGRP RECEPTOR ANTAGONISTS

Compounds of Formula (I): and Formula (II): (where variables R2, R4, A, B, D, W, X, Y and Z are as defined herein) useful as antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which the CGRP is involved, such as headache, migraine and cluster headache. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.